Quick access to main page (top) Direct access to main contents Quick access to main page (bottom)

Japanese Court Decides Surgery Not Mandatory for Gender Change

Daniel Kim Views  

Japan has made history by acknowledging a man as a woman without gender-affirming surgery. On July 10, the Yomiuri Shinbun reported that the Hiroshima High Court recognized the gender change on the family register when it was applied for by a party who did not meet the requirement of having reproductive organs that closely resembled the changed gender.

Last October, the Supreme Court of Japan ruled that the “Special Law on Gender Identity Disorder” provision, which essentially requires surgery to remove fertility, was declared unconstitutional, finding that it “forces an extreme choice between having surgery and giving up gender transition, and the degree of its limitation is severe.”

Declaring that the attendance requirement was not determined in the second trial, the court remanded the case to the High Court. The plaintiff presented was a person in their 40s living in western Japan and has never had gender-affirming surgery. They currently receive hormone therapy and live as a woman. “Forcing the patient to choose between giving up legal treatment according to their gender identity or undergoing surgery when needed infringements on the freedom not to harm the body seems unconstitutional,” the High Court stated in its ruling.

They continued, “It is not limited to cases where surgery has taken place, but when observed by others, there is no doubt that they are viewed as a woman.

The female-identifying person’s lawyer responded with, “I am pleased to be liberated from the difficulties experienced while living with the gap between my social gender and legal gender. I am truly grateful.”

Daniel Kim
content@viewusglobal.com

Comments0

300

Comments0

[LATEST] Latest Stories

  • Pfizer Ends Obesity Drug Trial After Liver Risk Emerges
  • Not Just Old Age: The Pneumonia That Affected Pope Francis’ Final Years
  • China Just Cranked U.S. Tariffs to 84% — And That’s Not the End of It
  • BMW's Next-Gen EV: The Bold New i3 Touring Concept Revealed
  • LEGO Technic Ferrari SF-24 F1 Car: A 1,361-Piece Tribute to Ferrari’s 2024 F1 Season
  • Hyundai’s Ioniq 6 Just Took the Top Spot in J.D. Power’s EV Ownership Study

You May Also Like

  • 1
    How Vitamin D Could Help Lower Colon Cancer Risk

    LIFESTYLE 

  • 2
    Yes, IVF Can Cause Weight Gain — Here's Why You Shouldn't Panic

    LIFESTYLE 

  • 3
    Red Jewels for Your Health: 7 Amazing Benefits of Pomegranates

    LIFESTYLE 

  • 4
    Hidden Danger: 5 'Healthy Foods' That Can Worsen Gout

    LIFESTYLE 

  • 5
    Spring’s Secret Weapon for Dry Coughs: Meet Liriope Tea

    LIFESTYLE 

Popular Now

  • 1
    FDA Approves $3.1M Gene Therapy for Rare, Painful Skin Disorder

    LIFESTYLE 

  • 2
    Experts Warn: Toss Your Expired Sunscreen Before It Hurts Your Skin

    LIFESTYLE 

  • 3
    New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier

    LIFESTYLE 

  • 4
    Bristol-Myers’ Schizophrenia Drug Falls Short in Key Trial

    LIFESTYLE 

  • 5
    Novavax COVID Vaccine Still on Hold—More Trials Needed, Says FDA

    LIFESTYLE 

Must-Reads

  • 1
    How Vitamin D Could Help Lower Colon Cancer Risk

    LIFESTYLE 

  • 2
    Yes, IVF Can Cause Weight Gain — Here's Why You Shouldn't Panic

    LIFESTYLE 

  • 3
    Red Jewels for Your Health: 7 Amazing Benefits of Pomegranates

    LIFESTYLE 

  • 4
    Hidden Danger: 5 'Healthy Foods' That Can Worsen Gout

    LIFESTYLE 

  • 5
    Spring’s Secret Weapon for Dry Coughs: Meet Liriope Tea

    LIFESTYLE 

Popular Now

  • 1
    FDA Approves $3.1M Gene Therapy for Rare, Painful Skin Disorder

    LIFESTYLE 

  • 2
    Experts Warn: Toss Your Expired Sunscreen Before It Hurts Your Skin

    LIFESTYLE 

  • 3
    New Drug Helps Patients with Myasthenia Gravis Breathe and Speak Easier

    LIFESTYLE 

  • 4
    Bristol-Myers’ Schizophrenia Drug Falls Short in Key Trial

    LIFESTYLE 

  • 5
    Novavax COVID Vaccine Still on Hold—More Trials Needed, Says FDA

    LIFESTYLE 

Share it on...